
RYBREVANT plus chemotherapy extends survival in advanced lung cancer with EGFR exon 20 mutations
Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a...





